title: Effect of the artificial sweetener, sucralose, on small intestinal glucose absorption in healthy human subjects.
abstract: It has been reported that the artificial sweetener, sucralose, stimulates glucose absorption in rodents by enhancing apical availability of the transporter GLUT2. We evaluated whether exposure of the proximal small intestine to sucralose affects glucose absorption and/or the glycaemic response to an intraduodenal (ID) glucose infusion in healthy human subjects. Ten healthy subjects were studied on two separate occasions in a single-blind, randomised order. Each subject received an ID infusion of sucralose (4 mM in 0.9% saline) or control (0.9% saline) at 4 ml/min for 150 min (T = - 30 to 120 min). After 30 min (T = 0), glucose (25 %) and its non-metabolised analogue, 3-O-methylglucose (3-OMG; 2.5 %), were co-infused intraduodenally (T = 0-120 min; 4.2 kJ/min (1 kcal/min)). Blood was sampled at frequent intervals. Blood glucose, plasma glucagon-like peptide-1 (GLP-1) and serum 3-OMG concentrations increased during ID glucose/3-OMG infusion (P < 0.005 for each). However, there were no differences in blood glucose, plasma GLP-1 or serum 3-OMG concentrations between sucralose and control infusions. In conclusion, sucralose does not appear to modify the rate of glucose absorption or the glycaemic or incretin response to ID glucose infusion when given acutely in healthy human subjects.
authors.affiliation: Discipline of Medicine, Royal Adelaide Hospital, University of Adelaide, North Terrace, Adelaide, SA 5000, Australia.
authors.forename: Jing
authors.initials: J
authors.lastname: Ma
authors.forename: Jessica
authors.initials: J
authors.lastname: Chang
authors.forename: Helen L
authors.initials: HL
authors.lastname: Checklin
authors.forename: Richard L
authors.initials: RL
authors.lastname: Young
authors.forename: Karen L
authors.initials: KL
authors.lastname: Jones
authors.forename: Michael
authors.initials: M
authors.lastname: Horowitz
authors.forename: Christopher K
authors.initials: CK
authors.lastname: Rayner
mesh_terms: D019325:3-O-Methylglucose / Q000097:blood*; D000328:Adult; D001786:Blood Glucose / Q000378:metabolism*; D005260:Female; D052216:Glucagon-Like Peptide 1 / Q000097:blood*; D005947:Glucose / Q000008:administration & dosage / Q000378:metabolism*; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects; D007421:Intestine, Small / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D012016:Reference Values; D016037:Single-Blind Method; D013395:Sucrose / Q000031:analogs & derivatives* / Q000494:pharmacology; D013549:Sweetening Agents / Q000494:pharmacology*
chemical_list: D001786:Blood Glucose; D013549:Sweetening Agents; D019325:3-O-Methylglucose; D013395:Sucrose; D052216:Glucagon-Like Peptide 1; C026285:trichlorosucrose; D005947:Glucose